Metastatic Anal Cancer and Novel Agents

Van Morris; Cathy Eng

doi:10.1016/j.soc.2016.07.008

Metastatic Anal Cancer and Novel Agents

Van Morris, Cathy Eng

GI Medical Oncology

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Squamous cell carcinoma of the anal canal (SCCA) represents an orphan disease. Although prior infection with human papilloma virus is associated with the development of SCCA, knowledge of this relationship has proven ineffective in identifying therapeutic agents that have activity in the management of metastatic SCCA. Combination chemotherapy with traditional cytotoxic agents has demonstrated efficacy in multiple small series. However, immune checkpoint blockade agents have demonstrated efficacy for patients with refractory metastatic SCCA; these agents hold promise in the horizon for patients with metastatic SCCA. Clinical trials should be considered for oncologists to manage patients with metastatic SCCA.

Original language	English (US)
Pages (from-to)	133-142
Number of pages	10
Journal	Surgical oncology clinics of North America
Volume	26
Issue number	1
DOIs	https://doi.org/10.1016/j.soc.2016.07.008
State	Published - Jan 1 2017

Keywords

Anal cancer
Chemotherapy
HPV
Immunotherapy
PD-1
Squamous cell

ASJC Scopus subject areas

Surgery
Oncology

MD Anderson CCSG core facilities

Clinical and Translational Research Center

Access to Document

10.1016/j.soc.2016.07.008

Cite this

@article{b21451f0f2ce4baf9b5549a2d436acab,

title = "Metastatic Anal Cancer and Novel Agents",

abstract = "Squamous cell carcinoma of the anal canal (SCCA) represents an orphan disease. Although prior infection with human papilloma virus is associated with the development of SCCA, knowledge of this relationship has proven ineffective in identifying therapeutic agents that have activity in the management of metastatic SCCA. Combination chemotherapy with traditional cytotoxic agents has demonstrated efficacy in multiple small series. However, immune checkpoint blockade agents have demonstrated efficacy for patients with refractory metastatic SCCA; these agents hold promise in the horizon for patients with metastatic SCCA. Clinical trials should be considered for oncologists to manage patients with metastatic SCCA.",

keywords = "Anal cancer, Chemotherapy, HPV, Immunotherapy, PD-1, Squamous cell",

author = "Van Morris and Cathy Eng",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2017",

month = jan,

day = "1",

doi = "10.1016/j.soc.2016.07.008",

language = "English (US)",

volume = "26",

pages = "133--142",

journal = "Surgical oncology clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Metastatic Anal Cancer and Novel Agents

AU - Morris, Van

AU - Eng, Cathy

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Squamous cell carcinoma of the anal canal (SCCA) represents an orphan disease. Although prior infection with human papilloma virus is associated with the development of SCCA, knowledge of this relationship has proven ineffective in identifying therapeutic agents that have activity in the management of metastatic SCCA. Combination chemotherapy with traditional cytotoxic agents has demonstrated efficacy in multiple small series. However, immune checkpoint blockade agents have demonstrated efficacy for patients with refractory metastatic SCCA; these agents hold promise in the horizon for patients with metastatic SCCA. Clinical trials should be considered for oncologists to manage patients with metastatic SCCA.

AB - Squamous cell carcinoma of the anal canal (SCCA) represents an orphan disease. Although prior infection with human papilloma virus is associated with the development of SCCA, knowledge of this relationship has proven ineffective in identifying therapeutic agents that have activity in the management of metastatic SCCA. Combination chemotherapy with traditional cytotoxic agents has demonstrated efficacy in multiple small series. However, immune checkpoint blockade agents have demonstrated efficacy for patients with refractory metastatic SCCA; these agents hold promise in the horizon for patients with metastatic SCCA. Clinical trials should be considered for oncologists to manage patients with metastatic SCCA.

KW - Anal cancer

KW - Chemotherapy

KW - HPV

KW - Immunotherapy

KW - PD-1

KW - Squamous cell

UR - http://www.scopus.com/inward/record.url?scp=85006326563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006326563&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2016.07.008

DO - 10.1016/j.soc.2016.07.008

M3 - Review article

C2 - 27889032

AN - SCOPUS:85006326563

SN - 1055-3207

VL - 26

SP - 133

EP - 142

JO - Surgical oncology clinics of North America

JF - Surgical oncology clinics of North America

IS - 1

ER -

Metastatic Anal Cancer and Novel Agents

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this